Attracting investors in the BioMedical sector isn’t just about securing funding—it’s about building trust with stakeholders who believe in the long-term impact of your innovations. Investors aren’t just looking for cutting-edge technology; they want proof of market potential, scalability, and a compelling business case.
That’s exactly what Certis Oncology Solutions needed when they partnered with Provoke Agency. With a breakthrough approach in precision oncology, they required a strategy that positioned them as an attractive investment opportunity.
Understanding the Challenge: Why Cold Outreach for Investors Fails
Problem: Certis Oncology had a strong scientific foundation but struggled to convert investor interest into actual funding conversations. Their email outreach lacked:
- Compelling storytelling – Messaging was too technical, focusing on science rather than investment potential.
- Follow-up consistency – Potential investors who showed interest weren’t nurtured effectively.
- Clear financial upside – Emails emphasized research milestones but failed to showcase ROI.
Solution: Provoke implemented a structured email marketing approach designed to capture investor attention, highlight market potential, and drive real engagement.
Step 1: Crafting Investor-Focused Messaging
Investors don’t just want to know what you do—they want to know why it matters and how it translates into financial success.
We replaced technical jargon with market impact. Instead of leading with “advanced ex vivo tumor models,” the new messaging emphasized:
→ “The $XX billion precision oncology market is projected to double by 2030. Certis Oncology’s breakthrough technology is positioned to capitalize on this demand.”
We included traction-based proof. Investors need to see that a business is gaining momentum. The email showcased:
- Current partnerships with research institutions
- Early-stage revenue growth
- Grants and industry recognition
We used investor-friendly language.
- Before: “Certis provides tumor-derived models for predictive oncology solutions.”
- After: “Certis helps pharmaceutical companies accelerate drug development and reduce clinical trial costs by up to 40%.”
Step 2: Segmenting Investor Leads for Personalized Outreach
Not all investors are the same. Some focus on early-stage startups, others on late-stage funding, and some prioritize impact-driven investments. To maximize response rates, we categorized investors into:
- Venture Capitalists (VCs): Highlighted growth potential and scalability.
- Angel Investors: Focused on disruptive innovation and market differentiation.
- Corporate Investors: Showcased partnerships and revenue-generating opportunities.
Each group received customized emails with messaging tailored to their specific investment thesis.
Step 3: Implementing a Multi-Touch Follow-Up Sequence
Cold emails rarely convert on the first attempt. Our investor outreach strategy followed a structured, multi-touch sequence:
1️Initial Introduction Email: Positioned Certis Oncology as a leader in precision oncology and emphasized market potential.
Follow-Up #1 (3 Days Later): Sent case studies and proof points showing how Certis’s technology reduces clinical trial costs.
Follow-Up #2 (1 Week Later): Highlighted recent funding milestones, partnerships, or media mentions.
Follow-Up #3 (Final Nurture Touchpoint): Included an exclusive invite to a private investor briefing call.
By automating and optimizing this sequence, Certis stayed top-of-mind while demonstrating persistence and credibility.
Step 4: Using Social Proof to Strengthen Investor Confidence
Investors trust data, but they also trust peer validation. We incorporated:
Testimonials from existing investors who had already backed Certis Oncology.
Press coverage and awards to reinforce industry recognition.
Metrics-driven success stories showcasing Certis’s impact on real-world clinical applications.
By adding a testimonial from a high-profile investor, we increased response rates by 42%.
The Results: Turning Cold Leads into Investor Conversations
Before partnering with Provoke, Certis Oncology struggled to convert investor interest into serious funding discussions. Within 90 days, our email marketing approach delivered:
3X Increase in Investor Engagement – Response rates jumped significantly, with investors requesting more details on funding rounds.
Higher Quality Leads – Investor meetings were scheduled with top-tier VCs, angel investors, and biotech funds.
Secured Early-Stage Funding – Certis successfully closed an investment deal to scale its technology and clinical partnerships.
Key Takeaways: How to Optimize Your Investor Email Outreach
Investors want financial potential, not just science. Lead with market size, revenue projections, and cost-saving impacts.
Follow-ups drive conversions. Most investor replies came after the second or third email—persistence matters.
Segment your investor list. A VC firm and an angel investor have different priorities—customize accordingly.
Use social proof. Highlight early investors, strategic partnerships, and real-world applications to reinforce trust.
Ready to Secure More Investors?
Finding the right investors for your BioMedical startup isn’t just about sending more emails—it’s about sending the right emails to the right people at the right time.
At Provoke Agency, we specialize in crafting high-impact investor outreach campaigns that generate real funding opportunities. If you’re looking to scale your BioMedical business and secure the backing you need, let’s talk.
Book a strategy session today and take your investor outreach to the next level.